Evidence map›Paper›PMID 34107229›Full record

ArticleAmerican journal of respiratory and critical care medicine2021

Reply to Andréasson

Roham T Zamanian, Ashley Pinckney, Robyn T Domsic, Thomas Medsger, Lynette Keyes-Elstein, Andrew J Sweatt, Beverly Welch, Ellen Goldmuntz, Mark R Nicolls, Lorinda Chung

Registry-linked trialAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of respiratory and critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01086540 (A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01086540 phase2completednot on this map

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2011 to 2019Enrolled57ConditionsSystemic Sclerosis-Associated PAHArmsRituximab, Placebo, CMRI, prednisone, methylprednisolone
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Roham T ZamanianStanford University School of Medicine Stanford, California.
Ashley PinckneyRho Federal Systems Division Durham, North Carolina.
Robyn T DomsicUniversity of Pittsburgh School of Medicine Pittsburgh, Pennsylvania.
Thomas MedsgerUniversity of Pittsburgh School of Medicine Pittsburgh, Pennsylvania.
Lynette Keyes-ElsteinRho Federal Systems Division Durham, North Carolina.
Andrew J SweattStanford University School of Medicine Stanford, California.
Beverly WelchNational Institute of Allergy and Infectious Diseases Bethesda, Maryland.
Ellen GoldmuntzNational Institute of Allergy and Infectious Diseases Bethesda, Maryland.
Mark R NicollsStanford University School of Medicine Stanford, California.
Lorinda ChungStanford University School of Medicine Stanford, California.

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Reclassifying Pulmonary Arterial Hypertension Into Immune Phenotypes Using Machine LearningK23HL151892 · NHLBI · STANFORD UNIVERSITY · PI SWEATT, ANDREW JOHN · 2020 to 2024
$942k
NHLBI NIH HHS K23 HL151892NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Scleroderma, SystemicWalkingHumans

Identifiers

PMID34107229
PMCPMC8513578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.